The FDA has granted retatrutide Fast Track designation, but as of January 2025 no phase 3 obesity or diabetes trial has reported primary outcomes [2]
[8],[53-55] Therefore, the inclusion of GLP-1RA or SGLT2i at the time of diagnosis of T2D in patients with ASCVD or multiple risk factors is a reasonable option and aligns with the views of Diabetes Canada
the HPLC purity threshold for each batch is disclosed on its Certificate of Analysis
Once approved, youll receive weekly injections and ongoing support from our team to help you succeed
What You Should Know: PatchMD, a pioneer in transdermal nutrient delivery, has unveiled its new GLP-1 Support Patch Collection, designed to provide essential support for individuals using GLP-1 receptor agonist medications such as Ozempic, Wegovy, and Mounjaro for weight management
Drug interaction considerations Weight loss peptides may interact with diabetes medications, requiring dose adjustments to prevent hypoglycemia